Search

everythinglearnresearchcommunity

for

Search:↓

Androgens, male hormones, affect physical and mental functions, with a decrease leading to health issues like muscle loss, bone disease, and depression, and more research is needed on long-term effects and treatments.

Finasteride before TURP reduces blood loss and slightly improves early postoperative quality of life.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.

Kolaviron and quercetin may help treat prostate issues.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Finasteride may reduce prostate bleeding by lowering blood vessel growth factor levels and blood vessel density in certain prostate areas.

Hair loss linked to prostate enlargement; stress and family history important factors.

Finasteride changes antioxidant enzyme expression, possibly affecting sperm protection in rats.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Testosterone with finasteride improved muscle and bone health in men with spinal cord injury.

Finasteride can cause sexual dysfunction, sperm changes, and affect bone density and metabolism.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Minoxidil can reduce functions related to androgen receptors.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.

Physical activity, height, and smoking affect prostate cancer risk.

Finasteride doesn't harm bone density in older men with BPH.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Finasteride may improve prostate cancer treatment outcomes.